TORONTO, Dec. 17, 2013 /CNW/ - Portage Biotech Inc. ("the Company")
(OTCQB: PTGEF, CNSX: PBT.U) ("Portage") is pleased to announce the
launch of its new web site, www.portagebiotech.com, which goes live today.
The site has been designed as an information centre for all interested
parties to easily follow our progress and will be updated from time to
time as further news develops.
Our subsidiary, Portage Pharmaceuticals Ltd ("PPL"), is currently
engaged in the following research and development activities:
Cell permeable peptide fusion proteins are in preclinical development
for the following indications:
Inflammatory eye diseases
Inflammatory skin diseases
In addition PPL has filed composition of matter and use patents and is
exploring opportunities for cell permeable fusion proteins that address
the following indications:
Polycystic kidney disease
Portage is engaged in researching and developing pharmaceutical and
biotech products through to clinical "proof of concept" with an initial
focus on unmet clinical needs and orphan drugs. Following proof of
concept, Portage will look to sell or license the products to large
pharmaceutical companies for further development and commercialization.
Portage, through its subsidiary, holds an exclusive worldwide licence in
non-oncology fields and the know-how relating to the Antennapedia
protein transduction technology developed by Trojantec. Antennapedia
("Antp"), is an unusual protein that allows for the delivery of drugs
into a cell and even into the nucleus which is often the desired site
of action. This protein coupled with a drug may even cross the blood
brain barrier. Portage is developing a research pipeline of Antp-based
drug candidates and evaluating their function and potential as new
therapeutic agents for a variety of non-oncology indications.
Portage management is looking to in license additional products to add
to its portfolio.
For further information, contact Greg Bailey, the Chairman at firstname.lastname@example.org or Kam Shah, Chief Financial Officer, at (416) 929-1806 or email@example.com and visit our websites www.portagebiotech.com and www.portagepharmaceuticals.com.
This news release includes forward-looking statements within the meaning
of the U.S. federal and Canadian securities laws. Any such statements
reflect Portage's current views and assumptions about future events and
financial performance. Portage cannot assure that future events or
performance will occur. Important risks and factors that could cause
actual results or events to differ materially from those indicated in
our forward-looking statements.
Portage assumes no obligation and expressly disclaims any duty to update
the information in this News Release.
SOURCE: Portage Biotech Inc.
For further information:
Contact Greg Bailey, the Chairman at firstname.lastname@example.org or Kam Shah, Chief Financial Officer, at (416) 929-1806 or email@example.com and visit our websites www.portagebiotech.com and www.portagepharmaceuticals.com.